Traders Purchase Large Volume of Assembly Biosciences Call Options (ASMB)

Share on StockTwits

Assembly Biosciences Inc (NASDAQ:ASMB) was the target of some unusual options trading on Monday. Stock traders acquired 2,876 call options on the stock. This is an increase of 2,317% compared to the average volume of 119 call options.

Assembly Biosciences stock opened at $14.78 on Tuesday. The stock has a market capitalization of $480.08 million, a price-to-earnings ratio of -3.71 and a beta of 1.75. Assembly Biosciences has a 12 month low of $13.13 and a 12 month high of $48.91.

Assembly Biosciences (NASDAQ:ASMB) last posted its earnings results on Thursday, February 28th. The biopharmaceutical company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($0.91) by ($0.12). The firm had revenue of $3.74 million during the quarter, compared to the consensus estimate of $3.69 million. Assembly Biosciences had a negative net margin of 613.02% and a negative return on equity of 57.48%. On average, equities research analysts anticipate that Assembly Biosciences will post -4.61 EPS for the current fiscal year.

Institutional investors have recently bought and sold shares of the business. Legal & General Group Plc raised its position in Assembly Biosciences by 17.0% in the fourth quarter. Legal & General Group Plc now owns 3,847 shares of the biopharmaceutical company’s stock valued at $87,000 after purchasing an additional 558 shares during the last quarter. Metropolitan Life Insurance Co. NY raised its position in Assembly Biosciences by 356.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 7,073 shares of the biopharmaceutical company’s stock valued at $160,000 after purchasing an additional 5,524 shares during the last quarter. Two Sigma Investments LP bought a new position in Assembly Biosciences in the fourth quarter valued at about $336,000. Point72 Asset Management L.P. bought a new position in Assembly Biosciences in the third quarter valued at about $407,000. Finally, New York State Common Retirement Fund raised its position in Assembly Biosciences by 15.3% in the fourth quarter. New York State Common Retirement Fund now owns 23,300 shares of the biopharmaceutical company’s stock valued at $527,000 after purchasing an additional 3,100 shares during the last quarter. Hedge funds and other institutional investors own 83.77% of the company’s stock.

Several analysts recently weighed in on ASMB shares. BidaskClub raised Assembly Biosciences from a “hold” rating to a “buy” rating in a research note on Thursday, February 14th. Zacks Investment Research raised Assembly Biosciences from a “hold” rating to a “buy” rating and set a $24.00 price objective on the stock in a research note on Thursday, February 21st. Finally, Chardan Capital reaffirmed a “hold” rating and issued a $30.00 price objective on shares of Assembly Biosciences in a research note on Monday. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Assembly Biosciences has an average rating of “Buy” and an average price target of $43.00.

TRADEMARK VIOLATION WARNING: “Traders Purchase Large Volume of Assembly Biosciences Call Options (ASMB)” was posted by Macon Daily and is the property of of Macon Daily. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://macondaily.com/2019/04/16/traders-purchase-large-volume-of-assembly-biosciences-call-options-asmb.html.

About Assembly Biosciences

Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.

See Also: Call Option

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.